U.S. markets open in 3 hours 49 minutes
  • S&P Futures

    3,792.25
    -24.50 (-0.64%)
     
  • Dow Futures

    31,084.00
    -152.00 (-0.49%)
     
  • Nasdaq Futures

    12,595.00
    -86.75 (-0.68%)
     
  • Russell 2000 Futures

    2,182.10
    -23.70 (-1.07%)
     
  • Crude Oil

    60.65
    -0.63 (-1.03%)
     
  • Gold

    1,708.60
    -7.20 (-0.42%)
     
  • Silver

    25.87
    -0.52 (-1.96%)
     
  • EUR/USD

    1.2044
    -0.0023 (-0.19%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.52
    +3.42 (+14.19%)
     
  • GBP/USD

    1.3936
    -0.0017 (-0.12%)
     
  • USD/JPY

    107.3470
    +0.3450 (+0.32%)
     
  • BTC-USD

    49,176.55
    -2,049.70 (-4.00%)
     
  • CMC Crypto 200

    986.55
    -0.66 (-0.07%)
     
  • FTSE 100

    6,588.15
    -87.32 (-1.31%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

NeutriSci Closes Financing

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER, BC / ACCESSWIRE / January 29, 2021/ NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that it has closed a non-brokered private placement (the "Placement") in which it raised gross proceeds of $370,050.

This Placement consisted of 2,467,000 units (the "Units") of the Company at a price of $0.15 per Unit. Each Unit consists of one common share and one half of one common share purchase warrant, with each whole warrant entitling the holder to acquire an additional common share of the Company at a price of $0.30 until January 29, 2023. All securities issued in connection with this Placement are subject to a hold period expiring May 30, 2021.

NeutriSci is using the net proceeds of the Placement for production runs relating to the product launch in Japan, and for general working capital purposes.

On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.

Glen Rehman
CEO
Tel: (403) 264-6320

For investor inquiries, please contact investors@neutrisci.com

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company's natural energy and focus supplement that has at its core, the beneficial effects of blueberries. For more information, please visit: www.neutrisci.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE: NeutriSci International Inc.



View source version on accesswire.com:
https://www.accesswire.com/626858/NeutriSci-Closes-Financing